Video

PARP Inhibitor Resistance in Ovarian Cancer Treatment

Author(s):

Bradley J. Monk, MD, FACS, FACOG,Robert L. Coleman, MD, FACOG, FACS

Experts discuss the best approach to treating patients with ovarian cancer who are resistant to PARP inhibitors.

Related Videos
Jennifer Scalici, MD
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Premal Thaker, MD, MS
Related Content
Whitney Goldsberry, MD
November 21st 2024

Olaparib Leads PARP Inhibitor Charge in the Treatment of BRCA-Mutated, HRD Ovarian Cancer

Vadim Gushchin, MD; Teresa Diaz-Montes, MD, MPH, FACOG
April 20th 2023

Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer

Gynecologic Oncology
November 14th 2024

Sacituzumab Tirumotecan Shows Antitumor Activity in Previously Treated Endometrial, Ovarian Cancers

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer
July 18th 2022

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

Kathleen N. Moore, MD, MS
November 12th 2024

Refined Definition of Platinum Resistance, Novel ADCs Could Bring More Changes to Ovarian Cancer Treatment

BT7480 in Nectin-4+, CD137+ Tumors | Image Credit: © Katsyarina - stock.adobe.com
November 7th 2024

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors